Walter M. Stadler

TL;DR: Angiogenesis inhibitors target the neovascular development that is hypothesized to underlie tumor growth as discussed by the authors, and they can be divided into five categories based on their target activity: 1) drugs that block matrix breakdown; 2) drugs which inhibit endothelial cells directly; 3) drugs targeting angiogenesis activators; 4) drugs attacking endothelial cell integrins or survival signaling; and 5) drugs with a currently unknown mechanism of action.

TL;DR: The present study provides the first example of gene expression profiling in peripheral blood, a clinically accessible surrogate tissue, for identifying patterns of geneexpression associated with higher likelihoods of positive outcome in patients with a solid tumor.

TL;DR: The trial was terminated early despite not meeting criteria for success or futility because of slow accrual and because the historical response rate became irrelevant with emerging data using sequential vascular endothelial growth factor therapies, nevertheless the observed progression-free and overall survival compare favorably to other phase II trials in this heavily pretreated population.

TL;DR: COSp16 loss is measurable in irrigation specimens and it correlates with clinical status, and this assay may prove useful in screening for and managing bladder cancer.

TL;DR: This phase 1 study employed an accelerated titration design followed by a 3+3 dose escalation to evaluate the safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BMS-936561 in patients with advanced ccRCC or B-NHL.